Addressing Rare and Genetic Diseases - Drug Discovery TOE

USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This edition of the Drug Discovery TOE depicts trends across rare and genetic diseases. In addition to key facts and findings, life sciences and pharmaceutical industry trends that are driving rare and genetic diseases interventions, as well as, the global macro trends demanding therapeutic solutions for rare and genetic diseases are illustrated.The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, sign

Table of Contents

Addressing Rare and Genetic Diseases - Drug Discovery TOETrend OverviewRare and Genetic DiseasesRare and Genetic DiseasesTechnology ProfilesInborn Errors of Metabolism and PediatricsGene Therapy and Plasma BiologicsUnique Solutions from Worldwide Innovative Companies Automatic DNA Sequencing and Genetic Diagnostic ServicesOrphan Product Development for Rare DisordersLysosomal Storage Disease to Finally get a BreakthroughNovel Research for Multiple Rare and Genetic DisordersAppendixPatent AnalysisPatent Analysis (continued)Patent Analysis (continued)Industry InteractionsIndustry Interactions (continued)

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.